Annual Meeting 2013 - Maintenance Olaparib for Severe Ovarian Cancer and a BRCA mutation - Dr. Jonathan Ledermann

Description: For more updates visit

Abstract #5505: Previously, we reported that maintenance treatment with the oral PARP inhibitor olaparib (400 mg bid) led to a significant PFS improvement vs placebo in patients (pts) with platinum-sensitive relapsed SOC (Ledermann et al NEJM2012).
Shared By : oncologyeducation
Posted on : 06/23/13
Added : 4 years ago
Category : Ovarian Cancer

More From oncologyeducation

Nothing found.